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Abstract: A 43-year-old Caucasian homosexual man with AIDS presented with blurring of 
vision, change of personality, and memory loss in March 1999. He had first been admitted 
2 months previously for treatment of Pneumocystis jiroveci pneumonia. A magnetic resonance 
imaging scan on admission showed multiple white matter lesions involving both subcortical 
cerebral hemispheres and cerebellar regions, with no mass effect or surrounding edema. JC virus 
was detected by nested polymerase chain reaction in the cerebrospinal fluid. These   findings 
were diagnostic of progressive multifocal leukoencephalopathy (PML). His CD4 count was 
34 cells/mL, and his HIV ribonucleic acid level was 800,789 copies/mL. He was treated with 
a combination antiretroviral therapy. He was last reviewed in October 2011. He was fully 
  independent socially and mentally, but he still had some residual neurologic signs with right-sided 
homonymous hemianopia and visual agnosia. His HIV ribonucleic acid level was undetectable, 
and his CD4 count was 574 cells/mm3. Although the median survival of patients with PML was 
poor before the antiretroviral therapy era, our patient, who is now aged 55 years, is still alive 
12 years after the diagnosis. The diagnosis of PML and differential diagnosis of focal neurologic 
signs in HIV-positive patients are discussed in this case report.
Keywords: HIV , focal neurologic signs, cerebral toxoplasmosis, primary brain lymphoma, 
ischaemic stroke
Case report
A 43-year-old Caucasian man with AIDS presented with progressive confusion,   blurring 
of vision, and personality change for 6 weeks in March 1999. He was successfully treated 
for Pneumocystis jiroveci pneumonia 2 months prior to his presentation. He did not have 
any headaches or seizures. He was afebrile. Examination revealed left cerebellar signs, 
dysphasia, and clear evidence of left posterior-occipital lesion with right homonymous 
hemianopia. He was unable to identify simple objects such as a pen or coins nor name 
colors correctly. He was disoriented in time and place. His CD4 count was 34 cells/
mm3. His HIV ribonucleic acid (RNA) level was 800,789 copies/mL. Serum toxoplasma 
immunoglobulin G antibodies were negative. A magnetic resonance imaging (MRI) 
scan on admission showed multiple white matter lesions involving both subcortical 
cerebral hemispheres and cerebellar regions, with no mass effect or surrounding edema 
(Figure 1). Cerebrospinal fluid (CSF) was clear in color with a polymorph count of 
three cells and a lymphocyte count of five cells. Gram staining of CSF did not show 
any organism, and bacterial culture of CSF was negative. CSF toxoplasma PCR was 
negative. CSF Mycobacterium tuberculosis culture was negative. JC virus antibodies 
in the blood and CSF were 1/81,920 and 1/20,489, respectively.1 The antibody index 
was 28, indicating intrathecal production of JC virus antibodies, which was consistent 
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with progressive multifocal leukoencephalopathy (PML). 
Nested PCR for JC virus was positive in the CSF.
He was treated with nucleoside reverse transcriptase 
  inhibitors, zidovudine (AZT), lamivudine, and the 
  non-nucleoside reverse transcriptase inhibitor nevirapine. His 
cerebellar signs improved 2 months after the treatment. He was 
oriented in time and place. He was able to walk independently 
to the local shops and to pay money correctly a year after 
admission. He became fully independent and able to live on 
his own nearly 2 years after his admission, though he required 
frequent visits by a support worker to supervise adherence to 
his antiretroviral therapy (ART). His HIV RNA level became 
undetectable, and his CD4 count rose to 330 cells/mm3. He 
developed symptoms of peripheral neuropathy 9 months after 
commencing ART. Zidovudine was replaced with abacavir. He 
was last reviewed in October 2011 when he was 55 years old. 
His adherence to ART was excellent without requiring any sup-
port from health care workers. He was fully independent and 
living on his own but still had some residual neurologic signs 
with homonymous hemianopia. He declined repeat lumbar 
puncture to look for JC virus in the CSF, as he felt that there 
was no reason to undergo invasive tests whilst he remained 
well. He is now reviewed in our HIV follow-up clinic every 
6 months. His most recent HIV RNA level was undetectable, 
and his CD4 count was 574 cells/mm3.
Discussion
PML is an opportunistic infection caused by a human 
polyomavirus, JC virus. The initial site of JC virus infec-
tion is thought to be the tonsils, and it is then carried via 
lymphocytes to the kidney and bone marrow, which are the 
sites of viral latency. Reactivation of JC virus occurs due to 
immunosuppression, and the virus crosses the blood–brain 
barrier within B lymphocytes and infects oligodendrocytes 
and astrocytes, causing widespread demyelinative lesions.2 
PML is an AIDS-defining illness in approximately 1%–3% of 
HIV-positive patients. It occurs almost exclusively in severely 
immunocompromised HIV-positive patients with CD4 counts 
less than 100 cells/mm3, as in our case.3 It was invariably fatal 
in patients with AIDS before the advent of ART, with median 
survival around 6 months. Our patient is still alive 12 years 
after the diagnosis of AIDS-related PML. Astrom et al4 first 
described PML in patients with chronic lymphocytic leukemia 
and Hodgkin’s lymphoma in 1958. Although the prevalence 
of PML increased significantly during the HIV epidemic, it 
has also been widely reported in other non-HIV conditions, 
such as systemic lupus erythematosus and sarcoidosis, and 
in patients with organ transplants.5 More recently, PML has 
also been associated with HIV-negative patients treated with 
immunomodulatory drugs, especially natalizumab.6,7 The risk 
of developing PML is 1.47 in 1000 in patients with multiple 
sclerosis who are treated with natalizumab, which is similar 
to the risk of developing PML (one in 1000) in patients with 
systemic lupus erythematosus who are treated with rituximab.8 
PML has also been reported in HIV-negative patients who are 
treated with other monoclonal antibodies such as efalizumab 
in patients with psoriasis. PML has also been recognized in 
HIV-negative patients with the use of immunosuppressive 
agents such as azathioprine, cyclophosphamide, methotrexate, 
mycophenolate, and fludaramine. Fludarabine is the most 
frequently implicated among immunosuppressive drugs with 
PML, as it is capable of depleting T lymphocytes.9
New onset of PML has been observed after initiation of 
ART. A rapid recovery of the immune system can trigger 
immune reconstitution inflammatory syndrome   (PML-IRIS), 
which is an inflammatory reaction to clinically   apparent or 
subclinical pathogens of JC virus.10 PML-IRIS has been 
reported in up to 23% of PML cases diagnosed in   HIV-positive 
patients.11 This inflammatory reaction is often associated with 
contrast enhancement with edema and   possible mass effect 
on an MRI scan. It is often acute in onset, and JC virus PCR 
in the CSF can be negative.12
PML patients present with a slow onset of focal   neurologic 
features without any headaches, fever, or altered consciousness. 
Hemiparesis, hemianopia, aphasia,   hemisensory defects, and 
ataxia are common features.   Headaches, seizures, and neck 
stiffness are rare in patients with PML.13 Other common 
causes of focal neurologic features in   HIV-positive patients 
Figure 1 Magnetic resonance imaging scan showing multifocal white matter lesions 
in both subcortical cerebral hemispheres and left cerebellar regions without any 
mass effect or surrounding edema.
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include cerebral toxoplasmosis and primary brain lymphoma. 
They often present with symptoms of raised intracranial 
pressure such as headaches or seizures and rapidly progres-
sive focal neurologic features. Radiologic imaging often 
shows multiple cerebral abscesses with surrounding edema 
in patients with cerebral toxoplasmosis and mass effect with 
cerebral edema in patients with primary brain lymphoma. 
Ischemic strokes in young AIDS patients causing focal neu-
rologic signs due to acquired deficiency of protein S and C 
have also been reported.14
For diagnosing PML, MRI is superior to computed 
tomography and shows multiple white matter lesions without 
any mass effect or surrounding edema, and lesions are not 
contrast enhancing. The occipito-parietal and frontal areas 
are most commonly affected. Lesions in thalamus, basal 
ganglia, corpus callosum, and posterior fossa are rare. In 
our patient, lesions were found in occipito-parietal areas, 
causing   homonymous hemianopia and visual agnosia, and 
in the cerebellum, causing cerebellar dysfunction.15 CSF is 
usually normal in terms of protein, glucose, and cell counts, 
which help to rule out other etiology such as cryptococcal 
  meningitis, tuberculous meningitis, or cerebral   toxoplasmosis. 
JC virus PCR of the CSF has been shown to have specificity 
(92%–99%) and sensitivity (75%).16 However, CSF PCR for 
JC virus can be negative in 25% of patients, especially in 
those with deep-seated lesions. Because JC virus is intermit-
tently shed in the CSF, repeated CSF analysis may increase 
the sensitivity. A negative PCR, therefore, will not exclude 
PML. Quantifying JC virus DNA level is a useful tool to 
monitor the disease progression of PML.17 This was not done 
in our patient, as it was not available at our hospital in 1999. 
JC virus antibodies in the CSF, in comparison with the blood 
in our patient, indicate that these antibodies are produced 
in the CSF and are not crossed from the blood. This was 
confirmed by a high antibody index.18,19 Definitive diagnosis 
is made by brain biopsy, which characteristically shows a 
triad of demyelination, enlarged nuclei with inclusions of 
oligodendrocytes, and giant bizarre astrocytes.20
There is no effective therapy for PML. However, cyto-
sine arabinoside, cidofovir, and meflaquine have been tried 
with various success.21–24 The prognosis has been improved 
with the use of ART, which suppresses HIV RNA level 
and improves immune function by raising CD4 counts. 
Regulatory protein Tat, which is found in HIV, is known 
to upregulate JC virus replication.25 The use of ART with 
a high central nervous system penetration effective score 
might be associated with prolonged survival of patients with 
HIV-related PML. Zidovudine and nevirapine have high CSF 
penetration scores. Hence, zidovudine and nevirapine are 
usually selected in the combination ART regimen in treat-
ing HIV-positive patients with PML. These agents halt the 
progression of demyelination by downregulating JC virus 
replication and improving survival, as in our patient.
Our patient, who was severely immunocompromised 
due to HIV infection, had clinical, virologic, and radiologic 
evidence of PML. Moreover, he did not have any other causes 
for his focal neurologic signs. The fact that the majority of 
his neurologic deficits improved with the rise of CD4 count 
due to the use of ART strongly suggests that his PML is 
in remission clinically following immune reconstitution 
12 years after the diagnosis of AIDS-related PML.
In conclusion, slowly progressive focal neurologic 
features without any headaches or seizures, and multiple 
subcortical white matter lesions without any mass effect or 
surrounding edema with positive JC virus DNA in the CSF 
in an AIDS patient, are diagnostic of PML. In addition, it is 
not invariably fatal after the introduction of ART.
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